Sanofi has struck a deal to buy Kymab for $1.1 billion upfront. The takeover will give Sanofi full global rights to an anti-OX40L monoclonal antibody that improved outcomes in atopic dermatitis patients in a midphase clinical trial last year. Source: Fierce Biotech 11/1/2021